Person:
Dries, Ruben

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Dries

First Name

Ruben

Name

Dries, Ruben

Filters

20191

Settings

Author's Publications: search.filters.isAuthorOfPublication.a9628f52-0b4e-44d1-a02a-ed6c4602ec89

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Publication
    BORIS Promotes Chromatin Regulatory Interactions in Treatment-Resistant Cancer Cells
    (Springer Science and Business Media LLC, 2019-08) Dries, Ruben; Seruggia, Davide; Gao, Yang; Sharma, Bandana; Huang, Hao; Moreau, Lisa; McLane, Michael; Marco, Eugenio; Chen, Ting; Yuan, Guo-Cheng; Young, Richard A.; Debruyne, David; Day, Daniel; Gray, Nathanael; Wong, Kwok-Kin; Orkin, Stuart; George, Rani; Sengupta, Satyaki
    The CCCTC-binding factor (CTCF), which anchors DNA loops that organize the genome into structural domains, plays a central role in gene control by facilitating or constraining interactions between genes and their regulatory elements. In cancer cells the disruption of CTCF binding at specific loci through somatic mutation or DNA hypermethylation5 results in the loss of loop anchors and consequent activation of oncogenes. By contrast, the germ cell-specific paralog of CTCF, BORIS (Brother of the Regulator of Imprinted Sites), is overexpressed in multiple cancers, but its contributions to the malignant phenotype remain unclear. Here we show that aberrant upregulation of BORIS promotes novel chromatin interactions in ALK-mutated, MYCN-amplified neuroblastoma cells rendered resistant to ALK inhibition. These cells are reprogrammed to a distinct phenotypic state during the acquisition of resistance, a process defined by the initial loss of MYCN expression followed by subsequent overexpression of BORIS and a concomitant switch in cellular dependence from MYCN to BORIS. The resultant BORIS-regulated alterations in chromatin looping lead to the formation of new super-enhancers that drive the ectopic expression of a subset of proneural transcription factors that ultimately define the resistance phenotype. These results identify a previously unrecognized role of BORIS – to engender regulatory chromatin interactions that support specific cancer phenotypes.